Nuclear particles are featured at the China-Hospeq 2026 Exhibition to track
In recent years, health information has continued to attract public attention, and the service capability of the industry has been improving. On the morning of August 14, 2026, the 32nd China International Medical Instrument Equipment Exhibition (China-Hospeq 2026), organized by the National Health Commission International Exchange and Cooperation Center, opened in Beijing. As a major industry platform for autonomous innovation in nuclear medical equipment, Nuclear Particle Medical Technology Limited (NYSE: Nuclear Particle Therapeutics Limited) is highlighting the latest autonomous innovations in the three core product lines of nuclear medical imaging, radiation therapy, neutron capture and diagnosis.
The exhibition focuses on providing high-quality leadership, co-building health care, and showcasing innovative medical equipment, digital medical technology and integrated solutions adapted to the needs of national health development along the country's national and transboundary routes. At the same time, China has more than 4 million new cases of malignant tumors per year, and the availability of accurate diagnostic and diagnostic equipment is directly related to the survival rate and quality of life of patients. In this context, the Nuclear Group responded to the call of the state to establish nuclear medical equipment as the core of the application of nuclear technology, and in 2019 founded the Nuclear Particles.
The Nuclear Particles have always adhered to the principle of nuclear helpers, protecting health, relying on the advantages of the Nuclear Group's industrial chain of nuclear technology applications, deepening the research and development, production and sales of high-end nuclear medical equipment, and continuing to promote the autonomous control of our country's high-end nuclear medical equipment. Based on the Group's 71 years of nuclear technology accumulation and complete nuclear technology industrial system, it has rapidly completed the transition from strategic blueprint planning, to the materialization of operations to the industrialization of cutting edge areas, achieving the key transition from technical catch-up to product landing. 1.
Nuclear Medical Imaging Equipment IntelliQuant Series Products: Clinical Integration Core Engine Nuclear Medicine Imaging is a key tool for early diagnosis of tumors, IntelliQuant970 (SPECT/CT) is an industry-first stand-alone cardiac dynamic imaging device, with proprietary 3D optical fusion imaging technology, with the highest resolution of small organ dynamic imaging in the industry, equipped with diagnostic level CT, and a comprehensive performance against imported high-end products. The three core product lines cover the entire exhibition, focusing on the core products of several innovative technologies and clinical practicality, covering the entire process of tumor diagnosis and diagnosis, further demonstrating the complete layout of core particles in the field of nuclear medicine. IntelliQuant930 ((SPECT) has been approved for three types of medical device registration certificates, image quality is more important than image products.
For the general public, the establishment of rational health concepts is especially important. Moreover, the product achieves 100% domestic production at subsystem level, 90% domestic production at component level. 2.
Medical electronic straight line accelerator VeloXLinac: VeloX breakthroughs accurate and accurate detection of CT and accelerator integrated barriers, achieving high-speed diagnostic image guidance at the diagnostic site, integrating intelligent mapping with automated programming, introducing online adaptive radiation time and space limits, and ultra-high-speed adaptive radiation regimens at the initial diagnostic site for high-speed diagnostic CT guidance. Currently, this equipment is becoming a key equipment for the national engineering center in Yangtze County and the strategic landing of the first group of cells in Yangtze County, and will also give new impetus to the development of national nuclear medicine along the way. 3.
Nitrogen capture and treatment equipment. In 2024, the successful acquisition of BNCT equipment by Shandong Provincial Oncology Medical Institute (BNCT) has become a key milestone in the domestic BNCT industrialization. Nuclear Particles-owned Nuclear Fuel Research and Development (NCPR) used high-flow straight-line accelerator technology and rotary pump technology, with three major advantages of ultra-thermal neutron beam flow, low harmful ingredients, low environmental radiation, and more than 95% domestic production rate.
As a state-owned high-tech enterprise, the year 2026 coincides with the year of excellence pursued by the Nuclear Group, and the development of nuclear particles, which must always have two main lines around hydrogen technology and hydrogen clinical practice, will grind each product with refined standards of excellence, and the products and technologies of nuclear particles will also be the key force to drive the production of hydrogen in the field of nuclear medicine. Facing a whole new path towards the development of high-quality lithium-ion batteries, nuclear particles are deeply implementing lithium-ion batteries to accelerate the completion of our high-end medical equipment shortcuts, accelerate key core technology offensives, breakthrough technology equipment bottlenecks, achieve the key indicative spirit of high-end medical equipment autonomous controlled batteries, adhere to the concept of self-innovation, market leadership and industrial collaboration, practice lithium as a nation-builder, the pioneer of a healthy democracy. At the same time, it is steadily advancing the internationalization of the domestic market, driving domestic nuclear medical equipment from industry and running to global leadership.
With the light of nuclear technology to light the lives of thousands of patients, to reform innovation, to adopt an outstanding stance of action, to invest in the power of central enterprises for the construction of a healthy China, to make autonomous and self-controlled China-made high-end nuclear medical equipment available to more patients in China and abroad. China's international medical service system is constantly monitoring the latest developments in the field of healthcare, to provide you with authority, reliable information and medical services. If you have further consultations on related content, welcome to contact authorized experts through the platform.
